Haemodynamic heterogeneity and treatment with the calcium channel blocker nicardipine during phaeochromocytoma surgery

被引:16
|
作者
Colson, P
Ryckwaert, F
Ribstein, J
Mann, C
Dareau, S
机构
[1] Hop Arnaud de Villeneuve, Serv Anesthesie Reanimat B, F-34295 Montpellier, France
[2] Hop Arnaud de Villeneuve, Serv Med Interne G, F-34295 Montpellier, France
关键词
surgery; pheochromocytoma; blood pressure; calcium antagonist;
D O I
10.1111/j.1399-6576.1998.tb05387.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Favourable outcome of phaeochromocytoma surgery requires that paroxysmal hypertension and arrhythmia be controlled, and that hypotension be prevented. Is nicardipine, a calcium channel blocking drug, always adequate ? Methods: Nineteen consecutive patients underwent surgery for phaeochromocytoma. Management was standardised with regards to anaesthesia and antihypertensive treatment. Nicardipine was used as a vasodilator and was given in order to maintain systemic vascular resistance lower than 1600 dyn.s.cm(-5). Results: Hypertension did not occur at any time during surgery in 6/19 patients. Blood pressure rose acutely in 3/19 patients at the time of tracheal intubation or surgical approach to the tumour, and was controlled by increased depth of anaesthesia. Hypertensive episodes occurred in 11/19 patients during tumour manipulation. Nicardipine always succeeded in maintaining low systemic vascular resistance but its dosage varied widely between patients (0.5 to 70 mg), a fact that may be accounted for by the striking intersubject variability of haemodynamic behaviour during surgery. In 7/11 patients, despite nicardipine treatment, sustained increase in blood pressure persisted with increased cardiac index, but low systemic vascular resistance. Following tumour removal, transient serious hypotension (MAP <60 mmHg) occurred in 4 patients, and was corrected by fluid volume expansion. Perioperative incidence of hypertension or hypotension was not related to preoperative clinical status. Conclusion: Adequate management of patients operated upon for phaeochromocytoma requires invasive monitoring, since the mechanisms underlying hypertensive crises are heterogeneous with regards to systemic vascular resistance and not predictable from preoperative data. Nicardipine provides a good control of vasoconstriction during phaeochromocytoma surgery with limited risk of serious hypotension after tumour removal.
引用
收藏
页码:1114 / 1119
页数:6
相关论文
共 50 条
  • [41] TREATMENT OF HYPERTENSIVE EMERGENCIES WITH THE CALCIUM-CHANNEL BLOCKER NIFEDIPINE
    BERTEL, O
    CONEN, LD
    AMERICAN JOURNAL OF MEDICINE, 1985, 79 (4A): : 31 - 35
  • [42] What Is the Best Treatment for Acute Calcium Channel Blocker Overdose?
    Olson, Kent R.
    ANNALS OF EMERGENCY MEDICINE, 2013, 62 (03) : 259 - 261
  • [43] Treatment Modalities in Calcium Channel Blocker Overdose: A Systematic Review
    Baid, Himanshi
    Kaeley, Nidhi
    Singh, Shiana
    Mahala, Prakash
    Chawang, Hannah
    Subhra, Soumya
    Manchanda, Harsimran
    Shankar, Takshak
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (08)
  • [44] Evaluation of the Treatment Approaches and Complications of Calcium Channel Blocker Intoxications
    Akinci, Emine
    Koylu, Ramazan
    Yortanli, Mehmet
    Cander, Basar
    EURASIAN JOURNAL OF EMERGENCY MEDICINE, 2013, 12 (04) : 189 - 194
  • [45] Treatment of sporadic hemiplegic migraine with calcium channel blocker verapamil
    Yu, WG
    Clark, NC
    Horowitz, SH
    NEUROLOGY, 2002, 58 (07) : A472 - A472
  • [46] N-type Calcium Channel Blocker for Pain Treatment
    Mao, Jianren
    PAIN MEDICINE, 2010, 11 (02) : 153 - 153
  • [47] Comparison of a negative dromotropic effect of L/N-type calcium channel blocker cilnidipine with that of L-type blocker nicardipine.
    Sugiyama, A
    Satoh, Y
    Nakamura, Y
    Hashimoto, K
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2003, 91 : 144P - 144P
  • [48] Dual calcium-channel blocker therapy in the treatment of hypertension
    Saseen, JJ
    Carter, BL
    ANNALS OF PHARMACOTHERAPY, 1996, 30 (7-8) : 802 - 810
  • [49] NICARDIPINE FOR THE TREATMENT OF RAYNAUD PHENOMENA - A DOUBLE-BLIND CROSSOVER TRIAL OF A NEW CALCIUM ENTRY BLOCKER
    RUPP, PAF
    MELLINGER, S
    KOHLER, J
    DORSEY, JK
    FURST, DE
    JOURNAL OF RHEUMATOLOGY, 1987, 14 (04) : 745 - 750
  • [50] Intravenous use of the calcium-channel blocker nicardipine as second-line treatment in severe, early-onset pre-eclamptic patients
    Hanff, LM
    Vulto, AG
    Bartels, PA
    Roofthooft, DWE
    Bijvank, BN
    Steegers, EAP
    Visser, W
    JOURNAL OF HYPERTENSION, 2005, 23 (12) : 2319 - 2326